| A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus DH Ilson, D Kelsen, M Shah, G Schwartz, DA Levine, J Boyd, M Capanu, ... Cancer 117 (7), 1409-1414, 2011 | 119 | 2011 |
| Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer B Miron, JH Hoffman-Censits, F Anari, J O’Neill, DM Geynisman, ... European urology oncology 3 (4), 544-547, 2020 | 62 | 2020 |
| Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer N Peled, LC Roisman, B Miron, R Pfeffer, RB Lanman, M Ilouze, A Dvir, ... Journal of Thoracic Oncology 12 (7), e81-e84, 2017 | 56 | 2017 |
| Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis D Ilson, M Bains, N Rizk, V Rusch, R Flores, B Park, M Shah, D Kelsen, ... Journal of Clinical Oncology 27 (15_suppl), 4573-4573, 2009 | 19 | 2009 |
| Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer JM Loree, Y Wang, MA Syed, AV Sorokin, O Coker, J Xiu, BA Weinberg, ... Clinical Cancer Research 27 (16), 4587-4598, 2021 | 18 | 2021 |
| Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer GY Ku, MA Shah, LH Tang, B Miron, DP Kelsen, DH Ilson Journal of Clinical Oncology 26 (15_suppl), 15580-15580, 2008 | 18 | 2008 |
| Comparative effectiveness of front-line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma KK Zarrabi, E Handorf, B Miron, MR Zibelman, F Anari, P Ghatalia, ... The Oncologist 28 (2), 157-164, 2023 | 13 | 2023 |
| Global meta-analysis of urine microbiome: colonization of polycyclic aromatic hydrocarbon–degrading bacteria among bladder cancer patients L Bukavina, I Isali, R Ginwala, M Sindhani, A Calaway, D Magee, B Miron, ... European Urology Oncology 6 (2), 190-203, 2023 | 10 | 2023 |
| Biomarker development for metastatic renal cell carcinoma: Omics, antigens, t-cells, and beyond B Miron, D Xu, M Zibelman Journal of Personalized Medicine 10 (4), 225, 2020 | 9 | 2020 |
| Revisited analysis of a SHIVA 01 trial cohort using functional mutational analyses successfully predicted treatment outcome M Kamal, G Tarcic, S Dureau, O Edelheit, Z Barbash, C Lecerf, C Morel, ... Molecular Oncology 12 (5), 594-601, 2018 | 6 | 2018 |
| Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma. B Miron, DM Geynisman European Urology 82 (4), 374-376, 2022 | 5 | 2022 |
| Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer KK Zarrabi, V Narayan, PJ Mille, MR Zibelman, B Miron, B Bashir, ... Therapeutic Advances in Urology 15, 17562872231182219, 2023 | 4 | 2023 |
| Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). B Miron, EA Ross, F Anari, J O'Neill, JH Hoffman-Censits, MR Zibelman, ... Journal of Clinical Oncology 37 (15_suppl), 4536-4536, 2019 | 4 | 2019 |
| Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors B Miron, E Handorf, K Zarrabi, MR Zibelman, F Anari, P Ghatalia, ... Urologic Oncology: Seminars and Original Investigations 40 (10), 454. e9-454 …, 2022 | 3 | 2022 |
| Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab. K Zarrabi, EA Handorf, B Miron, MR Zibelman, F Anari, P Ghatalia, ... Journal of Clinical Oncology 39 (15_suppl), 4551-4551, 2021 | 3 | 2021 |
| Re: The impact of COVID-19 vaccine on sperm quality WDC Maya, TS Omolaoye, SS du Plessis European Urology 82 (3), 327, 2022 | 2 | 2022 |
| Non-urothelial bladder cancer: Genomic alterations and patient outcomes. F Anari, B Miron, D Henson, D Arguello, ER Plimack, MR Zibelman, ... Journal of Clinical Oncology 37 (7_suppl), 399-399, 2019 | 2 | 2019 |
| Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial G Tarcic, M Kamal, O Edelheit, Z Barbash, M Vidne, B Miron, C Callens, ... European Journal of Cancer 69, S6-S7, 2016 | 2 | 2016 |
| Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer B Miron, BT Ristau, JJ Tomaszewski, J Jones, B Milestone, YN Wong, ... Urology Case Reports 9, 9-11, 2016 | 2 | 2016 |
| Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer B Miron, G Li, JCF Quintanilha, A Clark, T Scott, JS Ross, GR Oxnard, ... ESMO Real World Data and Digital Oncology 3, 100004, 2024 | 1 | 2024 |
